Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore.
Ocul Immunol Inflamm. 2023 Jul;31(5):1041-1060. doi: 10.1080/09273948.2022.2070503. Epub 2022 Jun 27.
This review aims to provide an update on the clinical presentation, etiologies, complications, and treatment options in intermediate uveitis (IU).
Narrative literature review.
IU affects all age groups with no clear gender predominance and has varied etiologies including systemic illnesses and infectious diseases, or pars planitis. In some instances, IU may be the sole presentation of an underlying associated condition or disease. Management of IU and its complications include administration of corticosteroids, antimetabolites, T-cell inhibitors, and/or biologics, along with surgical interventions, with varying degrees of effectiveness across literature. In particular, increasing evidence of the safety and efficacy of immunomodulatory agents and biologics has seen greater adoption of these therapies in clinical practice.
IU is an anatomical description of uveitis, involving intraocular inflammation of the vitreous, peripheral retinal vasculature, and pars plana. Various treatment options for intermediate uveitis are currently used in practice.
本综述旨在提供有关中间葡萄膜炎 (IU) 的临床表现、病因、并发症和治疗选择的最新信息。
叙述性文献综述。
IU 可影响所有年龄段，无明显性别优势，病因多种多样，包括系统性疾病和传染病，或睫状体平坦部炎。在某些情况下，IU 可能是潜在相关疾病或病症的唯一表现。IU 及其并发症的管理包括皮质类固醇、抗代谢物、T 细胞抑制剂和/或生物制剂的给药，以及手术干预，文献报道的疗效各不相同。特别是，免疫调节剂和生物制剂的安全性和有效性的证据不断增加，这些治疗方法在临床实践中的应用越来越广泛。
IU 是葡萄膜炎的解剖学描述，涉及玻璃体、周边视网膜血管和睫状体平坦部的眼内炎症。目前在临床实践中使用了各种治疗中间葡萄膜炎的方法。
